Toronto Dominion Bank bought a new position in shares of Iqvia Holdings Inc (NYSE:IQV) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 63,116 shares of the medical research company’s stock, valued at approximately $6,178,000.
A number of other hedge funds have also recently modified their holdings of IQV. Winslow Evans & Crocker Inc. purchased a new stake in shares of Iqvia in the 4th quarter valued at approximately $123,000. IFP Advisors Inc purchased a new stake in shares of Iqvia in the 4th quarter valued at approximately $200,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in shares of Iqvia in the fourth quarter valued at approximately $209,000. Atria Investments LLC acquired a new position in shares of Iqvia in the fourth quarter valued at approximately $218,000. Finally, First Quadrant L P CA acquired a new position in shares of Iqvia in the fourth quarter valued at approximately $221,000. 92.34% of the stock is currently owned by institutional investors.
A number of research analysts recently weighed in on IQV shares. TheStreet upgraded shares of Iqvia from a “c+” rating to a “b” rating in a report on Wednesday, December 13th. SunTrust Banks upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a report on Wednesday, March 7th. ValuEngine upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a report on Tuesday, February 20th. Zacks Investment Research upgraded shares of Iqvia from a “hold” rating to a “buy” rating and set a $112.00 price target for the company in a report on Thursday, January 18th. Finally, Royal Bank of Canada set a $118.00 price target on shares of Iqvia and gave the stock a “buy” rating in a report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $110.02.
In other news, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $101.21, for a total value of $1,012,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael J. Evanisko sold 816 shares of the stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $100.00, for a total transaction of $81,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,816 shares of company stock valued at $3,093,400. 6.00% of the stock is owned by insiders.
Iqvia Holdings Inc (IQV) traded down $0.84 during mid-day trading on Wednesday, reaching $104.84. 1,111,427 shares of the company traded hands, compared to its average volume of 1,186,370. The stock has a market cap of $22,062.05, a P/E ratio of 17.33, a price-to-earnings-growth ratio of 2.71 and a beta of 0.64. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.19 and a current ratio of 1.19. Iqvia Holdings Inc has a 1 year low of $76.80 and a 1 year high of $110.67.
Iqvia (NYSE:IQV) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.32 EPS for the quarter, missing the Zacks’ consensus estimate of $1.34 by ($0.02). The firm had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.09 EPS. research analysts anticipate that Iqvia Holdings Inc will post 2.84 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Equities Focus and is the property of of Equities Focus. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.equitiesfocus.com/2018/03/14/toronto-dominion-bank-invests-6-18-million-in-iqvia-holdings-inc-iqv-stock.html.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.